Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Stereotactic Radiosurgery for Perioptic Meningiomas: An International, Multicenter Study

A. Bunevicius, RK. Anand, M. Suleiman, AM. Nabeel, WA. Reda, SR. Tawadros, K. Abdelkarim, AMN. El-Shehaby, RM. Emad, T. Chytka, R. Liscak, K. Sheehan, D. Sheehan, MP. Caceres, D. Mathieu, CC. Lee, HC. Yang, P. Picozzi, A. Franzini, L. Attuati, H....

. 2021 ; 88 (4) : 828-837. [pub] 20210315

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019044

BACKGROUND: Stereotactic radiosurgery (SRS) is increasingly used for management of perioptic meningiomas. OBJECTIVE: To study the safety and effectiveness of SRS for perioptic meningiomas. METHODS: From 12 institutions participating in the International Radiosurgery Research Foundation (IRRF), we retrospectively assessed treatment parameters and outcomes following SRS for meningiomas located within 3 mm of the optic apparatus. RESULTS: A total of 438 patients (median age 51 yr) underwent SRS for histologically confirmed (29%) or radiologically suspected (71%) perioptic meningiomas. Median treatment volume was 8.01 cm3. Median prescription dose was 12 Gy, and median dose to the optic apparatus was 8.50 Gy. A total of 405 patients (93%) underwent single-fraction SRS and 33 patients (7%) underwent hypofractionated SRS. During median imaging follow-up of 55.6 mo (range: 3.15-239 mo), 33 (8%) patients experienced tumor progression. Actuarial 5-yr and 10-yr progression-free survival was 96% and 89%, respectively. Prescription dose of ≥12 Gy (HR: 0.310; 95% CI [0.141-0.679], P = .003) and single-fraction SRS (HR: 0.078; 95% CI [0.016-0.395], P = .002) were associated with improved tumor control. A total of 31 (10%) patients experienced visual decline, with actuarial 5-yr and 10-yr post-SRS visual decline rates of 9% and 21%, respectively. Maximum dose to the optic apparatus ≥10 Gy (HR = 2.370; 95% CI [1.086-5.172], P = .03) and tumor progression (HR = 4.340; 95% CI [2.070-9.097], P < .001) were independent predictors of post-SRS visual decline. CONCLUSION: SRS provides durable tumor control and quite acceptable rates of vision preservation in perioptic meningiomas. Margin dose of ≥12 Gy is associated with improved tumor control, while a dose to the optic apparatus of ≥10 Gy and tumor progression are associated with post-SRS visual decline.

Centro Gamma Knife Dominicano and CEDIMAT Radiology Department Santo Domingo Dominican Republic

Clinical Oncology Department Ain Shams University Cairo Egypt

Department of Neurosurgery Humanitas Clinical and Research Center IRCCS Milan Italy

Department of Neurosurgery Neurological Institute Taipei Veteran General Hospital Taipei Taiwan

Department of Neurosurgery Université de Sherbrooke Centre de recherche du CHUS Sherbrooke Québec Canada

Department of Neurosurgery University of Southern California Los Angeles California

Department of Neurosurgery University of Virginia Charlottesville Virginia

Department of Neurosurgery West Virginia University Morgantown West Virginia

Department of Radiation Oncology University of Colorado Denver Colorado

Department of Radiation Oncology University of Southern California Los Angeles California

Department of Radiation Oncology West Virginia University Morgantown West Virginia

Division of Radiation Oncology Department of Oncology University of Alberta Edmonton Canada

Gamma Knife Center Cairo Nasser Institute Hospital Cairo Egypt

Gamma Knife Center Jewish Hospital Mayfield Clinic Cincinnati Ohio

Neurosurgery Department Ain Shams University Cairo Egypt

Neurosurgery Department Benha University Qalubya Egypt

Radiation Oncology Department National Cancer Institute Cairo University Giza Egypt

School of Medicine National Yang Ming University Taipei Taiwan

Stereotactic and Radiation Neurosurgery Department Na Homolce Hospital Prague Czech Republic

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019044
003      
CZ-PrNML
005      
20210830100621.0
007      
ta
008      
210728s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1093/neuros/nyaa544 $2 doi
035    __
$a (PubMed)33475718
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bunevicius, Adomas $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia
245    10
$a Stereotactic Radiosurgery for Perioptic Meningiomas: An International, Multicenter Study / $c A. Bunevicius, RK. Anand, M. Suleiman, AM. Nabeel, WA. Reda, SR. Tawadros, K. Abdelkarim, AMN. El-Shehaby, RM. Emad, T. Chytka, R. Liscak, K. Sheehan, D. Sheehan, MP. Caceres, D. Mathieu, CC. Lee, HC. Yang, P. Picozzi, A. Franzini, L. Attuati, H. Speckter, J. Olivo, S. Patel, CP. Cifarelli, DT. Cifarelli, JD. Hack, BA. Strickland, G. Zada, EL. Chang, KR. Fakhoury, CG. Rusthoven, RE. Warnick, J. Sheehan
520    9_
$a BACKGROUND: Stereotactic radiosurgery (SRS) is increasingly used for management of perioptic meningiomas. OBJECTIVE: To study the safety and effectiveness of SRS for perioptic meningiomas. METHODS: From 12 institutions participating in the International Radiosurgery Research Foundation (IRRF), we retrospectively assessed treatment parameters and outcomes following SRS for meningiomas located within 3 mm of the optic apparatus. RESULTS: A total of 438 patients (median age 51 yr) underwent SRS for histologically confirmed (29%) or radiologically suspected (71%) perioptic meningiomas. Median treatment volume was 8.01 cm3. Median prescription dose was 12 Gy, and median dose to the optic apparatus was 8.50 Gy. A total of 405 patients (93%) underwent single-fraction SRS and 33 patients (7%) underwent hypofractionated SRS. During median imaging follow-up of 55.6 mo (range: 3.15-239 mo), 33 (8%) patients experienced tumor progression. Actuarial 5-yr and 10-yr progression-free survival was 96% and 89%, respectively. Prescription dose of ≥12 Gy (HR: 0.310; 95% CI [0.141-0.679], P = .003) and single-fraction SRS (HR: 0.078; 95% CI [0.016-0.395], P = .002) were associated with improved tumor control. A total of 31 (10%) patients experienced visual decline, with actuarial 5-yr and 10-yr post-SRS visual decline rates of 9% and 21%, respectively. Maximum dose to the optic apparatus ≥10 Gy (HR = 2.370; 95% CI [1.086-5.172], P = .03) and tumor progression (HR = 4.340; 95% CI [2.070-9.097], P < .001) were independent predictors of post-SRS visual decline. CONCLUSION: SRS provides durable tumor control and quite acceptable rates of vision preservation in perioptic meningiomas. Margin dose of ≥12 Gy is associated with improved tumor control, while a dose to the optic apparatus of ≥10 Gy and tumor progression are associated with post-SRS visual decline.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    12
$a internacionalita $7 D038622
650    _2
$a magnetická rezonanční tomografie $x metody $7 D008279
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a meningeální nádory $x diagnóza $x chirurgie $7 D008577
650    _2
$a meningeom $x diagnóza $x chirurgie $7 D008579
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nervus opticus $x chirurgie $7 D009900
650    _2
$a doba přežití bez progrese choroby $7 D000077982
650    _2
$a radiochirurgie $x metody $7 D016634
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Anand, Rithika Kormath $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia
700    1_
$a Suleiman, Mohanad $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia
700    1_
$a Nabeel, Ahmed M $u Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u Neurosurgery Department, Benha University, Qalubya, Egypt
700    1_
$a Reda, Wael A $u Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u Neurosurgery Department, Ain Shams University, Cairo, Egypt
700    1_
$a Tawadros, Sameh R $u Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u Neurosurgery Department, Ain Shams University, Cairo, Egypt
700    1_
$a Abdelkarim, Khaled $u Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u Clinical Oncology Department, Ain Shams University, Cairo, Egypt
700    1_
$a El-Shehaby, Amr M N $u Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u Neurosurgery Department, Ain Shams University, Cairo, Egypt
700    1_
$a Emad, Reem M $u Gamma Knife Center Cairo, Nasser Institute Hospital, Cairo, Egypt $u Radiation Oncology Department, National Cancer Institute, Cairo University, Giza, Egypt
700    1_
$a Chytka, Tomas $u Stereotactic and Radiation Neurosurgery Department, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Liscak, Roman $u Stereotactic and Radiation Neurosurgery Department, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Sheehan, Kimball $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia
700    1_
$a Sheehan, Darrah $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia
700    1_
$a Caceres, Marco Perez $u Department of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada
700    1_
$a Mathieu, David $u Department of Neurosurgery, Université de Sherbrooke, Centre de recherche du CHUS, Sherbrooke, Québec, Canada
700    1_
$a Lee, Cheng-Chia $u Department of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan $u School of Medicine, National Yang-Ming University, Taipei, Taiwan
700    1_
$a Yang, Huai-Che $u Department of Neurosurgery, Neurological Institute, Taipei Veteran General Hospital, Taipei, Taiwan $u School of Medicine, National Yang-Ming University, Taipei, Taiwan
700    1_
$a Picozzi, Piero $u Department of Neurosurgery, Humanitas Clinical and Research Center - IRCCS, Milan, Italy
700    1_
$a Franzini, Andrea $u Department of Neurosurgery, Humanitas Clinical and Research Center - IRCCS, Milan, Italy
700    1_
$a Attuati, Luca $u Department of Neurosurgery, Humanitas Clinical and Research Center - IRCCS, Milan, Italy
700    1_
$a Speckter, Herwin $u Centro Gamma Knife Dominicano and CEDIMAT Radiology Department, Santo Domingo, Dominican Republic
700    1_
$a Olivo, Jeremy $u Centro Gamma Knife Dominicano and CEDIMAT Radiology Department, Santo Domingo, Dominican Republic
700    1_
$a Patel, Samir $u Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Canada
700    1_
$a Cifarelli, Christopher P $u Department of Neurosurgery, West Virginia University, Morgantown, West Virginia $u Department of Radiation Oncology, West Virginia University, Morgantown, West Virginia
700    1_
$a Cifarelli, Daniel T $u Department of Neurosurgery, West Virginia University, Morgantown, West Virginia
700    1_
$a Hack, Joshua D $u Department of Radiation Oncology, West Virginia University, Morgantown, West Virginia
700    1_
$a Strickland, Ben A $u Department of Neurosurgery, University of Southern California, Los Angeles, California
700    1_
$a Zada, Gabriel $u Department of Neurosurgery, University of Southern California, Los Angeles, California
700    1_
$a Chang, Eric L $u Department of Radiation Oncology, University of Southern California, Los Angeles, California
700    1_
$a Fakhoury, Kareem R $u Department of Radiation Oncology, University of Colorado, Denver, Colorado
700    1_
$a Rusthoven, Chad G $u Department of Radiation Oncology, University of Colorado, Denver, Colorado
700    1_
$a Warnick, Ronald E $u Gamma Knife Center, Jewish Hospital, Mayfield Clinic, Cincinnati, Ohio
700    1_
$a Sheehan, Jason $u Department of Neurosurgery, University of Virginia, Charlottesville, Virginia
773    0_
$w MED00003511 $t Neurosurgery $x 1524-4040 $g Roč. 88, č. 4 (2021), s. 828-837
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33475718 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100621 $b ABA008
999    __
$a ok $b bmc $g 1689969 $s 1139490
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 88 $c 4 $d 828-837 $e 20210315 $i 1524-4040 $m Neurosurgery $n Neurosurgery $x MED00003511
LZP    __
$a Pubmed-20210728
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace